The Relationship Between Perioperative Use of Esketamine and Postpartum Depression Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
DOI: https://doi.org/10.2147/ndt.s451930
IF: 2.989
2024-05-17
Neuropsychiatric Disease and Treatment
Abstract:Yuansheng Cao, 1 Lijuan Fu, 1 Xianjie Zhang, 1 Leqiang Xia, 1 Rui Zhou 2 1 Department of Anesthesiology, Deyang People's Hospital, Deyang, People's Republic of China; 2 Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Translational Research Institute of Brain and Brain-Like Intelligence, Clinical Research Center for Anesthesiology and Perioperative Medicine, Department of Anesthesiology and Perioperative Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China Correspondence: Rui Zhou, Shanghai Fourth People's Hospital, No. 1279, Sanmen Road, Hongkou District, Shanghai, 200434, People's Republic of China, Email Purpose: To determine whether perioperative esketamine use decreases the risk of postpartum depression (PPD). Methods: Online search of PubMed, Web of Science, and Embase was conducted to identify relevant studies. Key words for search included, but were not limited to, postpartum depression, esketamine, and clinical trials. The mean and standard deviation of the Edinburgh Postnatal Depression Scale (EPDS) scores were extracted from the studies as primary parameters. Results: The literature search identified 226 articles, of which 5 met the criteria and were enrolled in the study. In total, 886 patients in the studies were taken into analysis. The EPDS scores in the esketamine group were lower than those of the control group at the early stage of puerperium (WMD=− 2.05, 95% CI: − 3.77, − 0.34, p =0.019), whereas there was no significant difference at the middle and later stages (WMD=− 1.41, 95% CI: − 2.86, 0.04, p =0.056). The sensitivity analyses indicated that the result for the early stage was stable, whereas it was unreliable for the middle and later stages. The results of the Egger's test indicated no publication bias. Conclusion: Perioperative use of esketamine contributes to a lower risk of PPD at the early stage of puerperium but not at the middle and later stages. To further verify this conclusion, more high-quality studies are required. Keywords: esketamine, postpartum depression, pregnant women, mental health Postpartum depression (PPD), one of the most common mental disorders in women, involves a series of physical, emotional, and psychological changes after childbirth. 1 The incidence of PPD was estimated to range from 12% to 17.7%. 2,3 The recurrence rate of a second pregnancy was reported to be a staggering proportion of about 40%. 4 PPD typically occurs within 4 post-childbirth weeks and can last throughout the puerperal period, sometimes lasting almost 3 years. 5 Untreated PPD is associated not only with impaired maternal physical health, frail psychological wellbeing, bad relationships, and risky behaviors, but also with infant outcomes, such as abnormal development of mental and physical health. 6 Although previous studies have identified several risk factors for PPD, such as psychosocial stressors, family and spousal support, income, and marriage, most of these risk factors are not modifiable. 7 Neuroregulatory techniques such as electroconvulsive therapy and transcranial magnetic stimulation are efficient at treating severe depression, but they add an additional economic burden. 8–10 In addition, prevention is more important than treatment. Therefore, it is necessary to take effective measures to prevent PPD. Esketamine, the S-enantiomer of ketamine, has a strong affinity for the N-methyl-D-aspartate receptor. In the treatment of depression, esketamine not only rapidly improves the symptoms of patients and reduces suicidal intention, but also has fewer adverse reactions. 11–13 Recently, esketamine was used to treat PPD. A single dose of esketamine failed to improve the incidence of PPD within 4 weeks. 14 However, some studies have concluded that intraoperative esketamine decreases the morbidity of PPD. 15–17 Given the role of esketamine in depression, it is potential to become a candidate for PPD prevention. However, the efficacy of esketamine for PPD prevention has not yet been determined. This study aimed to determine the role of esketamine in PPD prevention for parturients who underwent cesarean section. We hypothesized that perioperative use of esketamine would be helpful in decreasing the risk of PPD. This study is in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement. 18 Ethical approval and informed consent were not obtained. The study was not registered, and the study protocol was not applicable. PubMed, Web of Science and Embase were used to search for related -Abstract Truncated-
psychiatry,clinical neurology